Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update.
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company's executive chairman and controlling shareholder to be appointed as Company's interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY in Europe and South Africa and is negotiating additional license deals in Latin America and other territories NESS ZIONA, Israel, Aug. 17, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.
Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.15.
NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company specializing in treatments for severe skin conditions, is currently conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome. In addition to their two approved large-category dermatology products, TWYNEO® and EPSOLAY®, Sol-Gel announced today that they have entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. Ltd. in China for the commercialization of TWYNEO for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.